BN Business News
Add your company to Business Communicator →

Regulation & law · 22/10/2021

Ankarys Therapeutics to Receive Exclusive Patent License for CD28H Chimeric Antigen Receptors

The National Institute of Allergy and Infectious Diseases is considering granting Ankarys Therapeutics an exclusive patent license to use CD28H domain-containing chimeric antigen receptors and related methods, as outlined in patent applications listed in the notice.

Original source language: Federal Register — All DocumentsOpen original release →

Explore insights